• Je něco špatně v tomto záznamu ?

The Financial Burden of Localized and Metastatic Bladder Cancer

P. Scilipoti, M. Moschini, R. Li, SP. Lerner, PC. Black, A. Necchi, M. Rouprêt, SF. Shariat, S. Gupta, AK. Morgans, SP. Psutka, AM. Kamat

. 2025 ; 87 (5) : 536-550. [pub] 20241226

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, systematický přehled, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015979

BACKGROUND AND OBJECTIVE: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of treatment cost effectiveness. Here, we aim to systematically review and analyze the financial burden of BCa from the health care and patient perspectives. METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-compliant systematic review was conducted, searching PubMed/Medline, Embase, and public sources for studies evaluating the financial impact of BCa, encompassing costs, cost effectiveness, and financial toxicity (FT). KEY FINDINGS AND LIMITATIONS: Non-muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000-40 000 from surgical costs of RC, with additional expenses in case of complications. Trimodal therapy has higher costs (1-yr management cost >$200 000) than RC because of higher outpatient, radiology, and medication costs. Metastatic BCa incurs the highest financial burden, with systemic therapy costs ranging from $40 000 to over $100 000 per five-cycle course, increasing further with combination therapies (ie, enfortumab vedotin and pembrolizumab), treatment-related toxicity, and supportive care. FT is particularly prevalent among younger, less educated, and minority populations. CONCLUSIONS AND CLINICAL IMPLICATIONS: BCa treatment, particularly in advanced stages, imposes a substantial economic burden. Innovations in care, while improving oncologic outcomes, necessitate detailed cost-effectiveness assessments. Addressing these economic challenges is essential for optimizing BCa management, targeting patients at a higher risk of FT, and improving patient quality of life.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015979
003      
CZ-PrNML
005      
20250731091414.0
007      
ta
008      
250708s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2024.12.002 $2 doi
035    __
$a (PubMed)39730299
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Scilipoti, Pietro $u Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
245    14
$a The Financial Burden of Localized and Metastatic Bladder Cancer / $c P. Scilipoti, M. Moschini, R. Li, SP. Lerner, PC. Black, A. Necchi, M. Rouprêt, SF. Shariat, S. Gupta, AK. Morgans, SP. Psutka, AM. Kamat
520    9_
$a BACKGROUND AND OBJECTIVE: Bladder cancer (BCa) imposes a substantial economic burden on health care systems and patients. Understanding these financial implications is crucial for effective resource allocation and optimization of treatment cost effectiveness. Here, we aim to systematically review and analyze the financial burden of BCa from the health care and patient perspectives. METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-compliant systematic review was conducted, searching PubMed/Medline, Embase, and public sources for studies evaluating the financial impact of BCa, encompassing costs, cost effectiveness, and financial toxicity (FT). KEY FINDINGS AND LIMITATIONS: Non-muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000-40 000 from surgical costs of RC, with additional expenses in case of complications. Trimodal therapy has higher costs (1-yr management cost >$200 000) than RC because of higher outpatient, radiology, and medication costs. Metastatic BCa incurs the highest financial burden, with systemic therapy costs ranging from $40 000 to over $100 000 per five-cycle course, increasing further with combination therapies (ie, enfortumab vedotin and pembrolizumab), treatment-related toxicity, and supportive care. FT is particularly prevalent among younger, less educated, and minority populations. CONCLUSIONS AND CLINICAL IMPLICATIONS: BCa treatment, particularly in advanced stages, imposes a substantial economic burden. Innovations in care, while improving oncologic outcomes, necessitate detailed cost-effectiveness assessments. Addressing these economic challenges is essential for optimizing BCa management, targeting patients at a higher risk of FT, and improving patient quality of life.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x ekonomika $x terapie $x patologie $7 D001749
650    12
$a osobní újma zaviněná nemocí $7 D017281
650    _2
$a cystektomie $x ekonomika $x škodlivé účinky $7 D015653
650    12
$a náklady na zdravotní péči $7 D017048
650    _2
$a analýza nákladů a výnosů $7 D003362
650    _2
$a metastázy nádorů $7 D009362
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
655    _2
$a přehledy $7 D016454
700    1_
$a Moschini, Marco $u Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: moschini.marco@hsr.it
700    1_
$a Li, Roger $u Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA
700    1_
$a Lerner, Seth P $u Scott Department of Urology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA
700    1_
$a Black, Peter C $u Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
700    1_
$a Necchi, Andrea $u Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Rouprêt, Morgan $u Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, F-75013 PARIS, France
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Gupta, Shilpa $u Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Morgans, Alicia K $u Dana-Farber Cancer Institute, Boston, MA, USA
700    1_
$a Psutka, Sarah P $u Department of Urology, University of Washington School of Medicine, Seattle, WA, USA
700    1_
$a Kamat, Ashish M $u Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 87, č. 5 (2025), s. 536-550
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39730299 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091409 $b ABA008
999    __
$a ok $b bmc $g 2366671 $s 1253104
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 87 $c 5 $d 536-550 $e 20241226 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20250708
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace